- Home
- TSHA vs BBNX Comparison
TSHA vs BBNX Comparison
Compare TSHA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | BBNX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TSHA | BBNX |
|---|---|---|
| Price | $5.04 | $31.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $10.56 | ★ $28.92 |
| AVG Volume (30 Days) | ★ 3.4M | 887.5K |
| Earning Date | 02-25-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,310,000.00 | ★ $88,570,000.00 |
| Revenue This Year | N/A | $52.13 |
| Revenue Next Year | N/A | $36.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $1.05 | $8.89 |
| 52 Week High | $6.02 | $32.71 |
Technical Indicators
Market Signals| Indicator | TSHA | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 58.65 |
| Support Level | $4.80 | $28.36 |
| Resistance Level | $5.69 | $32.53 |
| Average True Range (ATR) | 0.31 | 1.67 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 18.44 | 79.86 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.